# Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

> clinical trial · VERIFIED · 2026-07-29

Status: RECRUITING · Sponsor: Sellas Life Sciences Group · Condition: Hematologic Malignancies

- Company: Sellas Life Sciences Group
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04588922

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.